Final results of a first-in-human phase I trial of PBI-05204, an inhibitor of AKT, FGF-2, NF-Kb, and p70S6K in advanced cancer patients.
H. A. Henary
No relevant relationships to disclose
R. Kurzrock
No relevant relationships to disclose
G. S. Falchook
No relevant relationships to disclose
A. Naing
No relevant relationships to disclose
S. L. Moulder
No relevant relationships to disclose
J. J. Wheler
No relevant relationships to disclose
A. M. Tsimberidou
No relevant relationships to disclose
J. Durand
No relevant relationships to disclose
P. Yang
Stock Ownership - Phoenix Biotechnology
Research Funding - Phoenix Biotechnology
M. J. Johansen
Consultant or Advisory Role - Scientific Advisory Board Member and Consultant
Stock Ownership - Phoenix Biotechnology
R. Newman
Consultant or Advisory Role - Phoenix Biotechnology
Stock Ownership - Phoenix Biotechnology
R. Khan
No relevant relationships to disclose
U. Patel
No relevant relationships to disclose
D. S. Hong
Research Funding - Eisai